Information About Our Center
The Eye Research Foundation has been successfully conducting clinical trials since 1998. Founded by Linda Wirta and Dr. Wirta, our mission is to provide a highly responsive clinical site where the latest in eye and cosmetic treatments can be tested with the highest standards of compliance and accuracy.
Our center is staffed by two physicians, and a clinical staff that includes a clinical manager (Linda Wirta) and six certified clinical coordinators who are double-certified as COA’s (Certified Ophthalmic Assistants). In addition, ancillary staff of Clinical Coordinator assistants, phlebotomists, and clerical/data-entry personnel are available. We have extensive experience in phase I-IV clinical trials, and have capacity for overnight Phase I and PK studies on site. Our areas of expertise include glaucoma/ocular hypertension, dry eye, presbyopia, blepharitis, post-cataract, cosmetic indications, healthy-normal studies, Japanese bridging studies, and other ophthalmic products. We specialize in single-site, Phase I, ophthalmology studies.
9 bed capacity
On-site overnight capabilities – 9 bed capacity
Off-site ASC Access
Off-site ASC access for aqueous humor sampling studies, and our surgical procedure projects
Phase I-IV study experience
Fully Engaged PI
Fully engaged PI (Dr. Wirta) and study center director (Linda Wirta)
On site phlebotomists
Latest Ophthalmology Equipment
Cirrus OCT, Humphrey VF, Konan endothelial cell camera, DGH ultrasound, Haag-Streit slit lamps, Goldman applanation tonometry, Atlas topography, etc.
Temperature controlled, monitored and secure drug storage (room temperature, refrigerated, -20, -70)
Serial PK blood sampling
On-site operating microscope for implant projects
100% Track Record
Track record of 100% of the time meeting or exceeding enrollment targets
Six certified clinical coordinators
Spacious monitoring rooms/capability for multiple simultaneous monitors
Two ECG machines
FDA Audit Experience
FDA audit experience, excellent track record with audit performance for pivotal trials